REG - AstraZeneca PLC - Directorate Change

AstraZenecaAnnouncement

22/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV0309Aa&default-theme=true

RNS Number : 0309A  AstraZeneca PLC  22 May 2023

22 May 2023   07:05 BST

 

Non-Executive Board Appointment

 

AstraZeneca PLC announced today that Anna Manz has been appointed as a
Non-Executive Director and a member of the Audit Committee with effect from 1
September 2023.

 

Anna is currently an Executive Director and the Group Chief Financial Officer
of London Stock Exchange Group plc.

 

Michel Demaré, Chair of AstraZeneca, said "We are delighted to welcome Anna
to the AstraZeneca Board. She brings extensive cross-sector business skills
and knowledge to the Board, having held international roles in North America
and Asia Pacific and served as an executive and non-executive in large, listed
companies. Anna's significant financial and strategic leadership experience,
including in areas such as risk, treasury and accounting, will enable her to
fully contribute to the work of our Audit Committee."

 

Biographical details - Anna Manz

Anna joined London Stock Exchange Group plc in November 2020 as Chief
Financial Officer, ahead of the $27 billion acquisition of Refinitiv. From
2016 - 2020, she was an Executive Director and the Chief Financial Officer of
Johnson Matthey Plc and led its Finance, Procurement and IT functions. Prior
to joining Johnson Matthey, Anna spent 17 years at Diageo plc in a number of
senior finance roles, including Chief Strategy Officer and as a member of the
Executive Committee. She brings extensive expertise in accounting, corporate
finance and mergers and acquisitions, as well as experience of business
diversification and transformation.

 

Anna has been a Non-Executive Director of ITV plc since 2016 and has served on
its Audit Committee and Remuneration Committee for most of that period. She
will step down as a Non-Executive Director of ITV at the end of August this
year.

 

Except as set out above, no disclosure obligations arise under paragraphs (1)
to (6) of LR 9.6.13 R of the UK Financial Conduct Authority's Listing Rules in
respect of this appointment.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASFSSAUEDSEII